v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 14, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name TREVI THERAPEUTICS, INC.    
Entity Central Index Key 0001563880    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 179.7
Entity Common Stock, Shares Outstanding   96,682,229  
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol TRVI    
Security Exchange Name NASDAQ    
Entity File Number 001-38886    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 45-0834299    
Entity Address, Address Line One 195 Church Street    
Entity Address, Address Line Two 16th Floor    
Entity Address, City or Town New Haven    
Entity Address, State or Province CT    
Entity Address, Postal Zip Code 06510    
City Area Code 203    
Local Phone Number 304-2499    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction false    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location New York, New York    
Auditor Opinion

We have audited the accompanying consolidated balance sheets of Trevi Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive loss, stockholders' equity and cash flows for the years then ended, and the related notes (collectively referred to as the “Consolidated Financial Statements”). In our opinion, the Consolidated Financial Statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

    
Documents Incorporated by Reference

Portions of the Proxy Statement for the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.